Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Chemotherapy, Nivolumab and Ipilimumab for Patients With Advanced KRAS Mutated Non-Small Cell Lung Cancer
This early-stage study is testing a special vaccine designed to help the body's immune system fight a specific type of advanced lung cancer. Researchers want to see if combining this vaccine with standard chemotherapy and immunotherapy is safe and effective.
You may be able to join if you have advanced non-small cell lung cancer with certain specific KRAS gene mutations and have not yet received treatment for this stage. Your overall health and ability to do light physical activity will also be checked.
Participants will receive standard chemotherapy and immunotherapy medications, followed by the KRAS-targeted vaccine. You will also need to provide tissue samples and undergo regular scans and blood tests so doctors can monitor your progress.
This study is currently recruiting patients in Baltimore, Maryland, United States. It is a smaller safety study looking to enroll about 15 people.
- 1Tests a new vaccine combined with standard chemo and immunotherapy for lung cancer.
- 2Requires tumors to have specific KRAS genetic mutations.
- 3Currently recruiting patients in Baltimore, Maryland.
Related video
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.